ThromboGenics announced its shareholders approved a new name for the company, Oxurion, at an extraordinary general meeting.
The name will be implemented in the coming days and weeks. The stock ticker symbol will change from “THR” to “OXUR,” according to a company press release.
“The new name, Oxurion, is designed to better reflect our ambition to deliver best-in-class therapies for back of the eye disorders. The renaming comes at a moment when we have delivered important clinical milestones and are accelerating the development of our unique pipeline of